255 related articles for article (PubMed ID: 36788585)
1. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.
Terp SK; Stoico MP; Dybkær K; Pedersen IS
Clin Epigenetics; 2023 Feb; 15(1):24. PubMed ID: 36788585
[TBL] [Abstract][Full Text] [Related]
2. Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.
Zhou F; Tao G; Chen X; Xie W; Liu M; Cao X
Clin Chem Lab Med; 2014 May; 52(5):735-42. PubMed ID: 24327526
[TBL] [Abstract][Full Text] [Related]
3. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer.
Singh A; Gupta S; Badarukhiya JA; Sachan M
Int J Cancer; 2020 Sep; 147(6):1740-1752. PubMed ID: 32191343
[TBL] [Abstract][Full Text] [Related]
4. Application of multiplex nested methylated specific PCR in early diagnosis of epithelial ovarian cancer.
Wang B; Yu L; Yang GZ; Luo X; Huang L
Asian Pac J Cancer Prev; 2015; 16(7):3003-7. PubMed ID: 25854397
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer detection by DNA methylation in cervical scrapings.
Wu TI; Huang RL; Su PH; Mao SP; Wu CH; Lai HC
Clin Epigenetics; 2019 Nov; 11(1):166. PubMed ID: 31775891
[TBL] [Abstract][Full Text] [Related]
6. Cumulative methylation alternations of gene promoters and protein markers for diagnosis of epithelial ovarian cancer.
Xing BL; Li T; Tang ZH; Jiao L; Ge SM; Qiang X; OuYang J
Genet Mol Res; 2015 May; 14(2):4532-40. PubMed ID: 25966226
[TBL] [Abstract][Full Text] [Related]
7. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer.
Widschwendter M; Zikan M; Wahl B; Lempiäinen H; Paprotka T; Evans I; Jones A; Ghazali S; Reisel D; Eichner J; Rujan T; Yang Z; Teschendorff AE; Ryan A; Cibula D; Menon U; Wittenberger T
Genome Med; 2017 Dec; 9(1):116. PubMed ID: 29268796
[TBL] [Abstract][Full Text] [Related]
8. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
[TBL] [Abstract][Full Text] [Related]
9. Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation.
Gao Y; Zhou N; Liu J
Cancer Control; 2024; 31():10732748241255548. PubMed ID: 38764160
[TBL] [Abstract][Full Text] [Related]
10. Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement.
Faaborg L; Fredslund Andersen R; Waldstrøm M; Høgdall E; Høgdall C; Adimi P; Jakobsen A; Dahl Steffensen K
Clin Chim Acta; 2021 Nov; 522():152-157. PubMed ID: 34419462
[TBL] [Abstract][Full Text] [Related]
11. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
Marinelli LM; Kisiel JB; Slettedahl SW; Mahoney DW; Lemens MA; Shridhar V; Taylor WR; Staub JK; Cao X; Foote PH; Burger KN; Berger CK; O'Connell MC; Doering KA; Giakoumopoulos M; Berg H; Volkmann C; Solsrud A; Allawi HT; Kaiser M; Vaccaro AM; Albright Crawford C; Moehlenkamp C; Shea G; Deist MS; Schoolmeester JK; Kerr SE; Sherman ME; Bakkum-Gamez JN
Gynecol Oncol; 2022 Jun; 165(3):568-576. PubMed ID: 35370009
[TBL] [Abstract][Full Text] [Related]
12. Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancer.
Liang L; Zhang Y; Li C; Liao Y; Wang G; Xu J; Li Y; Yuan G; Sun Y; Zhang R; Li X; Nian W; Zhao J; Zhang Y; Zhu X; Wen X; Cai S; Li N; Wu L
EBioMedicine; 2022 Sep; 83():104222. PubMed ID: 35973389
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
[TBL] [Abstract][Full Text] [Related]
14. Blood-based DNA methylation as biomarker for breast cancer: a systematic review.
Tang Q; Cheng J; Cao X; Surowy H; Burwinkel B
Clin Epigenetics; 2016; 8():115. PubMed ID: 27895805
[TBL] [Abstract][Full Text] [Related]
15. Detection of ovarian cancer using plasma cell-free DNA methylomes.
Lu H; Liu Y; Wang J; Fu S; Wang L; Huang C; Li J; Xie L; Wang D; Li D; Zhou H; Rao Q
Clin Epigenetics; 2022 Jun; 14(1):74. PubMed ID: 35681212
[TBL] [Abstract][Full Text] [Related]
16. Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases.
Wasenang W; Chaiyarit P; Proungvitaya S; Limpaiboon T
Clin Epigenetics; 2019 Mar; 11(1):39. PubMed ID: 30832707
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.
Li B; Pu K; Ge L; Wu X
Gene; 2019 Sep; 714():143993. PubMed ID: 31330238
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating methylated opioid binding protein/cell adhesion molecule-like gene as a biomarker for ovarian carcinoma.
Zhou F; Ma M; Tao G; Chen X; Xie W; Wang Y; Cao X
Clin Lab; 2014; 60(5):759-65. PubMed ID: 24839818
[TBL] [Abstract][Full Text] [Related]
20. Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers.
Miller BF; Pisanic Ii TR; Margolin G; Petrykowska HM; Athamanolap P; Goncearenco A; Osei-Tutu A; Annunziata CM; Wang TH; Elnitski L
Clin Epigenetics; 2020 Oct; 12(1):154. PubMed ID: 33081832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
